Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 3/2018

16.10.2017 | Original Article

Simultaneous whole-body 18F–PSMA-1007-PET/MRI with integrated high-resolution multiparametric imaging of the prostatic fossa for comprehensive oncological staging of patients with prostate cancer: a pilot study

verfasst von: Martin T. Freitag, Claudia Kesch, Jens Cardinale, Paul Flechsig, Ralf Floca, Matthias Eiber, David Bonekamp, Jan P. Radtke, Clemens Kratochwil, Klaus Kopka, Markus Hohenfellner, Albrecht Stenzinger, Heinz-Peter Schlemmer, Uwe Haberkorn, Frederik Giesel

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Introduction

The aim of the present study was to explore the clinical feasibility and reproducibility of a comprehensive whole-body 18F–PSMA-1007-PET/MRI protocol for imaging prostate cancer (PC) patients.

Methods

Eight patients with high-risk biopsy-proven PC underwent a whole-body PET/MRI (3 h p.i.) including a multi-parametric prostate MRI after 18F–PSMA-1007-PET/CT (1 h p.i.) which served as reference. Seven patients presented with non-treated PC, whereas one patient presented with biochemical recurrence. SUVmean-quantification was performed using a 3D–isocontour volume-of-interest. Imaging data was consulted for TNM-staging and compared with histopathology. PC was confirmed in 4/7 patients additionally by histopathology after surgery. PET-artifacts, co-registration of pelvic PET/MRI and MRI-data were assessed (PI-RADS 2.0).

Results

The examinations were well accepted by patients and comprised 1 h. SUVmean-values between PET/CT (1 h p.i.) and PET/MRI (3 h p.i.) were significantly correlated (p < 0.0001, respectively) and similar to literature of 18F–PSMA-1007-PET/CT 1 h vs 3 h p.i. The dominant intraprostatic lesion could be detected in all seven patients in both PET and MRI. T2c, T3a, T3b and T4 features were detected complimentarily by PET and MRI in five patients. PET/MRI demonstrated moderate photopenic PET-artifacts surrounding liver and kidneys representing high-contrast areas, no PET-artifacts were observed for PET/CT. Simultaneous PET-readout during prostate MRI achieved optimal co-registration results.

Conclusions

The presented 18F–PSMA-1007-PET/MRI protocol combines efficient whole-body assessment with high-resolution co-registered PET/MRI of the prostatic fossa for comprehensive oncological staging of patients with PC.
Literatur
1.
Zurück zum Zitat Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, et al. The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:197–209. CrossRefPubMed Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, et al. The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:197–209. CrossRefPubMed
2.
Zurück zum Zitat Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B, et al. Evaluation of hybrid 68Ga-PSMA-ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56:668–74. CrossRefPubMed Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B, et al. Evaluation of hybrid 68Ga-PSMA-ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56:668–74. CrossRefPubMed
3.
Zurück zum Zitat Eder M, Schäfer M, Bauder-Wüst U, Hull W-E, Wängler C, Mier W, et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem. 2012;23:688–97. CrossRefPubMed Eder M, Schäfer M, Bauder-Wüst U, Hull W-E, Wängler C, Mier W, et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem. 2012;23:688–97. CrossRefPubMed
4.
Zurück zum Zitat Foss CA, Mease RC, Fan H, Wang Y, Ravert HT, Dannals RF, et al. Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2005;11:4022–8. CrossRef Foss CA, Mease RC, Fan H, Wang Y, Ravert HT, Dannals RF, et al. Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2005;11:4022–8. CrossRef
5.
Zurück zum Zitat Mease RC, Dusich CL, Foss CA, Ravert HT, Dannals RF, Seidel J, et al. N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2008;14:3036–43. CrossRef Mease RC, Dusich CL, Foss CA, Ravert HT, Dannals RF, Seidel J, et al. N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2008;14:3036–43. CrossRef
6.
Zurück zum Zitat Chen Y, Pullambhatla M, Foss CA, Byun Y, Nimmagadda S, Senthamizhchelvan S, et al. 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2011;17:7645–53. CrossRef Chen Y, Pullambhatla M, Foss CA, Byun Y, Nimmagadda S, Senthamizhchelvan S, et al. 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2011;17:7645–53. CrossRef
7.
Zurück zum Zitat Rowe SP, Gage KL, Faraj SF, Macura KJ, Cornish TC, Gonzalez-Roibon N, et al. 18F-DCFBC PET/CT for PSMA-based detection and characterization of primary prostate cancer. J Nucl Med Off Publ Soc Nucl Med. 2015;56:1003–10. Rowe SP, Gage KL, Faraj SF, Macura KJ, Cornish TC, Gonzalez-Roibon N, et al. 18F-DCFBC PET/CT for PSMA-based detection and characterization of primary prostate cancer. J Nucl Med Off Publ Soc Nucl Med. 2015;56:1003–10.
8.
Zurück zum Zitat Szabo Z, Mena E, Rowe SP, Plyku D, Nidal R, Eisenberger MA, et al. Initial evaluation of [(18)F]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer. Mol Imaging Biol MIB Off Publ Acad Mol Imaging. 2015;17:565–74. CrossRef Szabo Z, Mena E, Rowe SP, Plyku D, Nidal R, Eisenberger MA, et al. Initial evaluation of [(18)F]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer. Mol Imaging Biol MIB Off Publ Acad Mol Imaging. 2015;17:565–74. CrossRef
9.
Zurück zum Zitat Cardinale J, Schafer M, Benešova M, Bauder-Wust U, Leotta K, Eder M, et al. Preclinical evaluation of [18F]PSMA-1007: a new PSMA-ligand for prostate cancer imaging. J Nucl Med. 2017;58:425–31. CrossRefPubMed Cardinale J, Schafer M, Benešova M, Bauder-Wust U, Leotta K, Eder M, et al. Preclinical evaluation of [18F]PSMA-1007: a new PSMA-ligand for prostate cancer imaging. J Nucl Med. 2017;58:425–31. CrossRefPubMed
10.
Zurück zum Zitat Giesel FL, Hadaschik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W, et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2017;44:678–88. CrossRefPubMed Giesel FL, Hadaschik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W, et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2017;44:678–88. CrossRefPubMed
11.
Zurück zum Zitat Freitag MT, Radtke JP, Afshar-Oromieh A, Roethke MC, Hadaschik BA, Gleave M, et al. Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in (68)Ga-PSMA-11-PET of PET/CT and PET/MRI: comparison with mpMRI integrated in simultaneous PET/MRI. Eur J Nucl Med Mol Imaging. 2017;44:776–87. CrossRefPubMed Freitag MT, Radtke JP, Afshar-Oromieh A, Roethke MC, Hadaschik BA, Gleave M, et al. Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in (68)Ga-PSMA-11-PET of PET/CT and PET/MRI: comparison with mpMRI integrated in simultaneous PET/MRI. Eur J Nucl Med Mol Imaging. 2017;44:776–87. CrossRefPubMed
12.
Zurück zum Zitat Afshar-Oromieh A, Haberkorn U, Schlemmer HP, Fenchel M, Eder M, Eisenhut M, et al. Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience. Eur J Nucl Med Mol Imaging. 2014;41:887–97. CrossRefPubMed Afshar-Oromieh A, Haberkorn U, Schlemmer HP, Fenchel M, Eder M, Eisenhut M, et al. Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience. Eur J Nucl Med Mol Imaging. 2014;41:887–97. CrossRefPubMed
13.
Zurück zum Zitat Eiber M, Weirich G, Holzapfel K, Souvatzoglou M, Haller B, Rauscher I, et al. Simultaneous 68Ga-PSMA HBED-CC PET/MRI improves the localization of primary prostate cancer. Eur Urol. 2016;70:829–36. CrossRefPubMed Eiber M, Weirich G, Holzapfel K, Souvatzoglou M, Haller B, Rauscher I, et al. Simultaneous 68Ga-PSMA HBED-CC PET/MRI improves the localization of primary prostate cancer. Eur Urol. 2016;70:829–36. CrossRefPubMed
14.
Zurück zum Zitat Freitag MT, Radtke JP, Hadaschik BA, Kopp-Schneider A, Eder M, Kopka K, et al. Comparison of hybrid (68)Ga-PSMA PET/MRI and (68)Ga-PSMA PET/CT in the evaluation of lymph node and bone metastases of prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43:70–83. CrossRefPubMed Freitag MT, Radtke JP, Hadaschik BA, Kopp-Schneider A, Eder M, Kopka K, et al. Comparison of hybrid (68)Ga-PSMA PET/MRI and (68)Ga-PSMA PET/CT in the evaluation of lymph node and bone metastases of prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43:70–83. CrossRefPubMed
15.
Zurück zum Zitat Freitag MT, Fenchel M, Bäumer P, Heußer T, Rank CM, Kachelrieß M, et al. Improved clinical workflow for simultaneous whole-body PET/MRI using high-resolution CAIPIRINHA-accelerated MR-based attenuation correction. Eur J Radiol. 2017;96:12–20. Freitag MT, Fenchel M, Bäumer P, Heußer T, Rank CM, Kachelrieß M, et al. Improved clinical workflow for simultaneous whole-body PET/MRI using high-resolution CAIPIRINHA-accelerated MR-based attenuation correction. Eur J Radiol. 2017;96:12–20.
16.
Zurück zum Zitat Weinreb JC, Barentsz JO, Choyke PL, Cornud F, Haider MA, Macura KJ, et al. PI-RADS prostate imaging – reporting and data system: 2015, version 2. Eur Urol. 2016;69:16–40. CrossRefPubMed Weinreb JC, Barentsz JO, Choyke PL, Cornud F, Haider MA, Macura KJ, et al. PI-RADS prostate imaging – reporting and data system: 2015, version 2. Eur Urol. 2016;69:16–40. CrossRefPubMed
18.
Zurück zum Zitat Wallis CJD, English JC, Goldenberg SL. The role of resection of pulmonary metastases from prostate cancer: a case report and literature review. Can Urol Assoc J. 2011;5:e104–8. CrossRefPubMedPubMedCentral Wallis CJD, English JC, Goldenberg SL. The role of resection of pulmonary metastases from prostate cancer: a case report and literature review. Can Urol Assoc J. 2011;5:e104–8. CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Somford DM, Hamoen EH, Fütterer JJ, van Basten JP, Hulsbergen-van de Kaa CA, Vreuls W, et al. The predictive value of endorectal 3 tesla multiparametric magnetic resonance imaging for extraprostatic extension in patients with low, intermediate and high risk prostate cancer. J Urol. 2013;190:1728–34. CrossRefPubMed Somford DM, Hamoen EH, Fütterer JJ, van Basten JP, Hulsbergen-van de Kaa CA, Vreuls W, et al. The predictive value of endorectal 3 tesla multiparametric magnetic resonance imaging for extraprostatic extension in patients with low, intermediate and high risk prostate cancer. J Urol. 2013;190:1728–34. CrossRefPubMed
20.
Zurück zum Zitat Radtke JP, Hadaschik BA, Wolf MB, Freitag MT, Schwab C, Alt C, et al. The impact of magnetic resonance imaging on prediction of extraprostatic extension and prostatectomy outcome in patients with low-, intermediate- and high-risk prostate cancer: try to find a standard. J Endourol. 2015;29:1396–405. CrossRefPubMed Radtke JP, Hadaschik BA, Wolf MB, Freitag MT, Schwab C, Alt C, et al. The impact of magnetic resonance imaging on prediction of extraprostatic extension and prostatectomy outcome in patients with low-, intermediate- and high-risk prostate cancer: try to find a standard. J Endourol. 2015;29:1396–405. CrossRefPubMed
21.
Zurück zum Zitat Koerber SA, Utzinger MT, Kratochwil C, Kesch C, Haefner M, Katayama S, et al. (68)Ga-PSMA11-PET/CT in newly diagnosed carcinoma of the prostate: correlation of intraprostatic PSMA uptake with several clinical parameters. J Nucl Med Off Publ Soc Nucl Med. 2017. Koerber SA, Utzinger MT, Kratochwil C, Kesch C, Haefner M, Katayama S, et al. (68)Ga-PSMA11-PET/CT in newly diagnosed carcinoma of the prostate: correlation of intraprostatic PSMA uptake with several clinical parameters. J Nucl Med Off Publ Soc Nucl Med. 2017.
22.
Zurück zum Zitat Lederer CM, Shirley VS, Browne E, editors. Table of isotopes. 7th ed. New York: Wiley; 1978. Lederer CM, Shirley VS, Browne E, editors. Table of isotopes. 7th ed. New York: Wiley; 1978.
24.
Zurück zum Zitat Heußer T, Mann P, Rank CM, Schäfer M, Dimitrakopoulou-Strauss A, Schlemmer H-P, et al. Investigation of the halo-artifact in 68Ga-PSMA-11-PET/MRI. PLoS One. 2017;12:e0183329. CrossRefPubMedPubMedCentral Heußer T, Mann P, Rank CM, Schäfer M, Dimitrakopoulou-Strauss A, Schlemmer H-P, et al. Investigation of the halo-artifact in 68Ga-PSMA-11-PET/MRI. PLoS One. 2017;12:e0183329. CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Afshar-Oromieh A, Wolf M, Haberkorn U, Kachelrieß M, Gnirs R, Kopka K, et al. Effects of arm truncation on the appearance of the halo artifact in 68Ga-PSMA-11 (HBED-CC) PET/MRI. Eur J Nucl Med Mol Imaging. 2017. Afshar-Oromieh A, Wolf M, Haberkorn U, Kachelrieß M, Gnirs R, Kopka K, et al. Effects of arm truncation on the appearance of the halo artifact in 68Ga-PSMA-11 (HBED-CC) PET/MRI. Eur J Nucl Med Mol Imaging. 2017.
26.
Zurück zum Zitat Blumhagen JO, Ladebeck R, Fenchel M, Scheffler K. MR-based field-of-view extension in MR/PET: B0 homogenization using gradient enhancement (HUGE). Magn Reson Med. 2013;70:1047–57. CrossRefPubMed Blumhagen JO, Ladebeck R, Fenchel M, Scheffler K. MR-based field-of-view extension in MR/PET: B0 homogenization using gradient enhancement (HUGE). Magn Reson Med. 2013;70:1047–57. CrossRefPubMed
27.
Zurück zum Zitat Rezaei A, Salvo K, Vahle T, Panin V, Casey M, Boada F, et al. Plane-dependent ML scatter scaling: 3D extension of the 2D simulated single scatter (SSS) estimate. Phys Med Biol. 2017;62:6515–31. CrossRefPubMed Rezaei A, Salvo K, Vahle T, Panin V, Casey M, Boada F, et al. Plane-dependent ML scatter scaling: 3D extension of the 2D simulated single scatter (SSS) estimate. Phys Med Biol. 2017;62:6515–31. CrossRefPubMed
Metadaten
Titel
Simultaneous whole-body 18F–PSMA-1007-PET/MRI with integrated high-resolution multiparametric imaging of the prostatic fossa for comprehensive oncological staging of patients with prostate cancer: a pilot study
verfasst von
Martin T. Freitag
Claudia Kesch
Jens Cardinale
Paul Flechsig
Ralf Floca
Matthias Eiber
David Bonekamp
Jan P. Radtke
Clemens Kratochwil
Klaus Kopka
Markus Hohenfellner
Albrecht Stenzinger
Heinz-Peter Schlemmer
Uwe Haberkorn
Frederik Giesel
Publikationsdatum
16.10.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 3/2018
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-017-3854-6

Weitere Artikel der Ausgabe 3/2018

European Journal of Nuclear Medicine and Molecular Imaging 3/2018 Zur Ausgabe